TNFSF11 and osteoporosis: This study evaluates the risk of stroke (ischemic or hemorrhagic) and myocardial infarction (MI) among postmenopausal women and men initiating osteoporosis treatment with denosumab (RANKL inhibitor) or zoledronic acid (bisphosphonate).